Bortezomib induces ROS-dependent mitochondrial apoptosis and suppresses SKP2 signaling in cutaneous T-cell lymphoma cells
Cutaneous T-cell lymphomas (CTCL) are skin-homing T-cell malignancies characterized by recurrent disease, therapeutic resistance and limited durable treatment responses in advanced stages. Although the proteasome inhibitor bortezomib has demonstrated activity in CTCL, the molecular pathways associated with its an...